ArticleAmerican journal of respiratory and critical care medicine2023
Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine.
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD.Stem cell research & therapy · 2026Review
- Mesenchymal stem cells and derived extracellular vesicles in major respiratory diseases: from multifaceted molecular mechanisms to clinical perspectives.Frontiers in cell and developmental biology · 2026Review
- Imaging in animal models: bridging experimental findings and human pathophysiology.Critical care (London, England) · 2025Review
- Advancements in Plant-Derived sRNAs Therapeutics: Classification, Delivery Strategies, and Therapeutic Applications.International journal of molecular sciences · 2025Review
- Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.Frontiers in immunology · 2025Review
- Reply to Zhu: Mesenchymal Stromal Cells in Acute Respiratory Distress Syndrome: Shoulder Heavy Responsibilities, and a Long Way to Go.American journal of respiratory and critical care medicine · 2024Article
- Mesenchymal Stromal Cells in Acute Respiratory Distress Syndrome: Shoulder Heavy Responsibilities, and a Long Way to Go.American journal of respiratory and critical care medicine · 2024Article
- An early HMGB1 rise 12 hours before creatinine predicts acute kidney injury and multiple organ failure in a smoke inhalation and burn swine model.Frontiers in immunology · 2024Article
- Multipotent mesenchymal stromal/stem cell-based therapies for acute respiratory distress syndrome: current progress, challenges, and future frontiers.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Review
- Mesenchymal Stromal Cells in Acute Respiratory Distress Syndrome: More Questions Than Answers.American journal of respiratory and critical care medicine · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.